Search Results

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, in Baltimore, MD.

Scale Biosciences announced the availability of ScalePlex an advanced single cell multiplexing technology designed to simplify large-scale single cell genomics studies.

Gamida Cell today announced new executive leadership following a successful restructuring transaction (“Transaction”) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) on May 24, 2024.

SHINE Technologies, LLC, a pioneer in next-generation fusion-based technology, becomes North America’s largest producer of non-carrier added lutetium-177 chloride, a cutting-edge radiopharmaceutical used in precision cancer treatment, with a Drug Master File to the U.S. Food and Drug Administration.

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent acquisition executives from Bristol Myers Squibb and Intellia Therapeutics offer an inside look at what they want in an employee.

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T

Q&A: Development Scientist at AGC Biologics Sara Morlacchi analyzes the growth of the cell therapy industry and barriers for cost and accessibility.

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.

As traditional fundraising methods falter for smaller firms, the rise of royalty deals is reshaping how companies access capital, offering an alternative that bypasses equity dilution and debt.